SAN DIEGO, Nov. 19, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 10:00 a.m. Eastern Time in New York.
A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.mirati.com. Replays of the presentation will be available at the same location for 60 days following the conference.
About Mirati Therapeutics
Mirati Therapeutics is a targeted oncology company developing oncology therapeutics for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development – drug candidates targeting genetic and epigenetic drivers of cancer, creative and agile clinical development that selects for patients whose tumors are dependent on those driver alterations, and a highly accomplished precision medicine leadership team. The Mirati team is using a blueprint proven by their prior work for developing potential breakthrough therapies with accelerated development paths. Mirati is currently advancing three drug candidates through clinical development for multiple oncology indications. More information is available at www.mirati.com.
Mirati Therapeutics Inc.
Mark J. Gergen
Executive Vice President & COO
Investor Relations and Media Relations:
SOURCE Mirati Therapeutics, Inc.